Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 4/20 | 0.58 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.58 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.58 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307397 | 0.81 | GAK (0.66) | GAKRIPK2COQ8ANLKL3MBTL1 | |
| SCHEMBL19283173 | 0.81 | GAK (0.66) | GAKRIPK2COQ8ANLKL3MBTL1 | |
| SCHEMBL29096082 | 0.79 | SYK (0.57) | GAKRIPK2COQ8ANLKSMN1; SMN2 | |
| SCHEMBL96953 | 0.79 | SYK (0.57) | GAKRIPK2COQ8ANLKSMN1; SMN2 | |
| SCHEMBL27797044 | 0.78 | SYK (0.56) | GAKRIPK2COQ8ANLKSMN1; SMN2 | |
| SCHEMBL21264425 | 0.75 | MEN1 (0.55) | RIPK2SMN1; SMN2L3MBTL1KDM4EMAPT | |
| SCHEMBL460384 | 0.75 | SYK (0.57) | GAKRIPK2COQ8ANLKSMN1; SMN2 | |
| SCHEMBL6126214 | 0.74 | SMN1; SMN2 (0.64) | SMN1; SMN2HSD17B10L3MBTL1KDM4EMAPT | |
| SCHEMBL1172280 | 0.74 | IGF1R (0.67) | GAKRIPK2COQ8ANLKSMN1; SMN2 | |
| SCHEMBL8976490 | 0.74 | RET (0.65) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | GAK 267/4885RIPK2 143/4885COQ8A 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.